相关实验视频
Updated: Jun 22, 2025

06:26
Novel and Innovative Hybrid Technique for Type A Aortic Dissection
Published on: March 28, 2025
254
横弧支架及其对全身高血压的影响
İbrahim Halil Demir1, Murat Kardas1, İlker Kemal Yucel1
1Department of Pediatric Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul, Türkiye.
Turk gogus kalp damar cerrahisi dergisi
|June 27, 2024
概括
横向大动脉门支架是儿童患者高血压的安全有效治疗方法. 该程序显著改善了血压控制,并减少了对抗高血压药物的需求.
科学领域:
- 心血管外科心血管外科
- 儿童心脏病学 儿童心脏病学
- 干预心脏病学 干预心脏病学
背景情况:
- 系统性高血压可能会在经过凝心治疗后持续存在,原因是剩余的横向大动脉损伤.
- 横向大动脉门支架是处理这种病例的潜在干预措施.
研究的目的:
- 研究横向大动脉门支架的安全性和有效性.
- 评估门支架对全身高血压的影响.
主要方法:
- 对18名患者 (4-23岁) 的回顾性分析,这些患者在2007年至2023年期间接受了横向大动脉支架.
- 详细检查程序数据,技术方面,压力测量和结果.
- 评估早期和中期结果,包括并发症和血压控制.
主要成果:
- 支架显著增加了大动脉门直径,并减少了压力梯度.
- 没有早期死亡率或重大并发症; 一例晚期支架迁移.
- 三名患者在干预后变得正常紧张,5名患者在随访期间变得无药.
结论:
- 横向大动脉支架支架植入是安全有效的,改善血压控制.
- 由于持续高血压的风险,患者需要终身监测.
- 良好的结果表明支架作为一种可行的选择,用于管理导致高血压的残留损伤.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
Antihypertensive Drugs: Angiotensin II Receptor Blockers
700
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
700
Antihypertensive Drugs: Vasodilators
503
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
503

